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Abstract 
 
 
The respiratory tract is the target of multiple infectious agents.  Because the lungs are continually 
exposed to infectious pathogens in inspired air, natural defense mechanisms have devolved to 
prevent infection.  These defense mechanisms coordinate with each other to provide efficient 
protection against infection.  As a result, pulmonary infections can be viewed not just as a 
consequence of exposure to a virulent pathogen but as a result of a breakdown of natural host 
defenses.  SPLUNC1 or SPURT (secretory protein in upper respiratory tracts) is small, secreted 
protein that is expressed in epithelial areas of the nose, mouth, pharynx and lungs.  It may be 
involved in host defense because it is highly homologous to bactericidal/permeability-increasing 
protein (BPI); a protein that mediates LPS related bacteria killing. 
In this study, we established a constitutively overexpress CCSP-spurt transgenic mouse 
model to examine the biological function of spurt.  We compared mRNA expression of CCSP-
spurt in transgenic mice and their transgenic negative litermates.  We determined that mRNA 
expression of CCSP-spurt was elevated in transgenic mice.  The tissue distribution of 
overexpressed spurt in CCSP-spurt mice was confirmed to be only at trachea and lung and exist 
in no other tissues.  Bronchoalveolar lavage (BAL) fluid from unchallenged CCSP-spurt mice 
 iii
had higher spurt concentration as was determined by ELISA and western blot.  BAL from 
unchallenged CCSP-spurt mice also exhibited antibacterial activity.  Furthermore, CCSP-spurt 
mice display enhanced bacterial clearance than wild-type mice after both groups of mice were 
challenged with aerosolized gram negative microorganisms Pseudomonas aeruginosa (PAO1) 
infection.  BAL of CCSP-spurt mice had lower levels of proinflammatory cytokines than BAL of 
their wild-type littermates after the challenge with aerosolized P. aeruginosa. 
Results from our studies suggest that spurt is a novel BPI-like antibacterial protein that 
may play a critical role in airway specific innate immunity.  Further studies of this protein might 
have potential public health significance in providing better understanding of natural defense 
processes in respiratory tract. 
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1. INTRODUCTION 
 
 
 
 
The respiratory tract is the target of multiple infectious agents.  Because the lungs are continually 
exposed to infectious pathogens in inspired air, natural defense mechanisms have evolved to 
prevent infection, which include mucociliary transport, innate immunity, cell-mediated 
immunity, and antibody production.  These defense mechanisms coordinate with each other to 
provide efficient protection against infection.  As a result, pulmonary infections can be viewed 
not just as a consequence of exposure to a virulent pathogen but as a result of a breakdown of 
natural host defenses. 
Upper respiratory tract infections affect the airways in the nose, ears, and throat.  They 
can be caused by viruses, bacteria, or other microscopic organisms.  Acute pharyngitis accounts 
for 1% to 2% of all visits to outpatient and emergency departments, resulting in 7 million annual 
visits by adults alone [1].  It is estimated that 31 million to 35 million US citizens have sinus 
disease [2].  About 12 million individuals are diagnosed with acute tracheobronchitis annually, 
accounting for one-third of patients presenting with acute cough [3].  The estimated economic 
impact of non-influenza-related upper respiratory tract infections is $40 billion annually [4].  
However most of the upper respiratory tract infections are common and not serious.  Those 
infections are minimized by an efficient mucociliary escalator clearance mechanism, which is 
supported by antibacterial substances within the upper respiratory tract. 
Lower respiratory tract infections are the major cause of death in the world and the major 
cause of death due to infectious diseases in the United States.  Lower respiratory tract infection 
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(LRTI) describes a range of symptoms and signs, varying in severity from non-pneumonic LRTI 
in the young healthy adult through to pneumonia or life-threatening exacerbation in a patient 
with severe disabling chronic obstructive pulmonary disease (COPD).  LRTI is a particularly 
common and serious illness in the elderly.  In a population-based retrospective cohort study in 
Rochester, Minnesota, USA, approximately one in 18 residents older than 65 years experienced 
one or more episodes of bronchitis or pneumonia over one year, with an overall 30-day mortality 
of 10.7% [5].  
Pneumonia is a leading cause of death in the world and the sixth most common cause of 
death in the United States.  It is the number one cause of death from infectious diseases in the 
United States [6].  The overall rates of death due to pneumonia and influenza have increased by 
59% from 1979 through 1994 and by 22% when adjusted for age greater than 65 years[7].  
  Community-acquired pneumonia (CAP) is one of the most common infectious diseases 
addressed by clinicians.  Community-acquired pneumonia is caused most commonly by bacteria 
that traditionally have been divided into 2 groups, typical and atypical.  Typical organisms 
include S pneumoniae (pneumococcus) and Haemophilus and Staphylococcus species.  Atypical 
refers to pneumonia caused by Legionella, Mycoplasma, and Chlamydia species.  Less frequent, 
but still important, causative pathogens in CAP include Staphylococcus aureus, Escherichia coli, 
Klebsiella pneumoniae and Pseudomonas aeruginosa [8].  CAP is an important cause of mortality 
and morbidity worldwide.  Every year in the United States, there are from 5 million to 10 million 
cases of CAP leading to as many as 1.1 million hospitalizations and 45,000 deaths.  It costs about 
$7,500 to manage a single in-hospital case of CAP, an amount that is more than 20-fold higher 
than the cost of outpatient treatment ($150 to $350) [7].  The mortality rate is less than 1% for 
persons with CAP who do not require hospitalization; however, the mortality rate averages from 
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12% to 14% among hospitalized patients with CAP.  Among patients who are admitted to the 
intensive care unit (ICU), or who are bacteremic, or who are admitted from a nursing home, the 
mortality rate averages from 30% to 40% [6].   
In 2002, 11.2 million U.S. adults aged 18 years and older were estimated to have Chronic 
Obstructive Pulmonary Disease (COPD) [9].  Bacteria are isolated from between 40-60% of acute 
exacerbations of COPD. Three bacterial species account for most isolates: Haemophilus 
influenzae, Streptococcus pneumoniae and Moraxella cattarhalis.  Haemophilus parainfluenzae, 
Pseudomonas aeruginosa, Staphylococcus aureus and Enterobacteriaciae are encountered less 
frequently.  Haemophilus influenzae is present in about 50% of culture positive sputa in most 
clinical trials.  Variation in incidence between trials may be accounted for by patient selection 
criteria, previous antibiotic exposure and sputum culture techniques [10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 
21, 22, 23]. 
In general, timely recognition of bacterial products is critical for human survival.  The 
best studied constituent of gram negative bacteria is lipopolysaccharide (LPS).  LPS is a potent 
activator of innate immune responses that result in the production of pro- and anti-inflammatory 
mediators from myeloid lineages and other cell types.  In humans, numbers of proteins are 
important in mediating signals from LPS.  Two of those are bactericidal/permeability-increasing 
protein (BPI) and LPS-binding protein (LBP).  These proteins are structurally related, however 
their functions are antagonistic.  LBP has proinflammatory action and BPI has more direct 
bactericidal action [24].  SPLUNC1 or SPURT (secretory protein in upper respiratory tracts) is 
small, secreted protein that is expressed in epithelial areas of the nose, mouth, pharynx and lungs 
[25].  In this study we used genetically modified mouse model to do a functional characterization 
of SPLUNC1 (SPURT). 
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2. REVIEW OF THE RELEVANT LITERATURE 
 
 
 
 
Gram-negative bacteria possess an outer membrane composed of lipopolysaccharide (LPS; 
endotoxin), which protects the microorganism from harsh environmental extremes.  LPS 
contains 3 distinct components: (1) the O-polysaccharide chain, which confers strain specificity; 
(2) the deep-core region, which links the O-polysaccharide chain to the third component; and (3) 
lipid A.  The deep-core/lipid A regions are evolutionarily conserved throughout many genera of 
gram-negative bacteria.  The recognition of and response against this glycolipid by the host will 
provide protection against a wide range of microorganisms.  The innate immune system enables 
the host to mount an immediate response to variety of invading pathogens.  To recognize the 
presence of pathogens, innate immune cells express receptors that identify highly conserved 
pathogen-associated molecular structures.  Endotoxin is a pathogen-associated molecular pattern 
molecule for the pattern recognition receptor Toll-like receptor 4 (TLR4), which is found on 
many cells of the innate immune system, including macrophages [26, 27].  LBP and BPI are 
naturally occurring LPS binding proteins that bind LPS from the outer envelope of Gram-
negative bacteria and are structurally similar.  BPI is a 55kD mammalian host defense protein 
found in the primary granules of polymorphonuclear neutrophils.  It binds to the lipid A moiety 
of gram-negative bacteria and kills them by depolarizing the inner membrane [28].  BPI acts as an 
intracellular anti-bacterial protein.  Based on amino acid sequence comparison, BPI belongs to 
the same family of proteins as the human LPS binding protein (LBP), the cholesteryl ester 
transfer protein (CETP) and phospholipid transfer protein (PLTP).   
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PLUNC (palate lung and nasal epithelium clone) is a family of proteins.  The exact 
function of the PLUNC proteins is unknown.  PLUNC was identified while studying gene 
expression in the embryonic murine palate.  The new gene codes for a small, 26.7-kDa protein[38] 
and was expressed around developing palate and quite strongly in the nasal septum and nasal 
conchae as well as in trachea and main stem bronchi of adult mice[29].  LeClair et al. showed that 
PLUNC expression in the mouse upper airway is largely postnatal.  PLUNC is expressed as early 
as e14.5, is maintained during the latter stages of development and persist until adulthood [30].  
Growing number of related mammalian homologues of PLUNC are being identified.  So far the 
homologues of PLUNC were found in such species as mouse[30], human[31], rat[32], cow[33]and 
pigs[34].  
The PLUNC family of genes can be divided into two subgroups: the "Short" PLUNC 
genes (SPLUNCs) code for proteins of ~250 residues; while the "Long" PLUNC genes 
(LPLUNCs) code for ~ 480 residue proteins.  In humans, the PLUNC family of proteins are 
located in a 300Kb cluster on chromosome 20 [24, 35].  PLUNC gene cluster identified in humans 
corresponds to clusters on mouse chromosome 2 and rat chromosome 3 [35].  Figure 1 shows the 
human PLUNC gene cluster on chromosome 20q11.21.  The pale red box indicates the position 
of a pseudogene for the human orthologue of rodent LPLUNC5 and the blue arrows indicate the 
direction of transcription [36]. 
 
 
 
 
Figure 1  The human PLUNC locus [36]. 
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While the levels of amino acid identity are very low, typically 15%- 30% [37], between 
proteins of the PLUNC and BPI/ LBP/ CETP/ PLTP families, all proteins share a similar 
predicted fold, a single predicted disulphide bond, and a conserved exon structure.  It shows that 
PLUNC genes are clearly evolutionary related to each other and to BPI/LBP/CETP/PLTP 
families.  The LPLUNC proteins are have homology to both N- and C—terminal domains of BPI 
and are predicted to be structurally equivalent to whole BPI (red boxes Figure 1), while the 
SPLUNC proteins are equivalent to the N-terminal LPS binding domain alone (blue box 
).  Within the PLUNC family the sequence identity is rather low, ranging typically from 16% to 
28% with LPLUNC3 and LPLUNC4 sharing higher pairwise identity of 37% [24].  The low level 
of identity tends to support the hypothesis that those proteins might function in host defense.  
Among mammals there is big diversity among short PLUNC proteins, which might suggest that 
short genes evolved separately by duplication within certain mammalian lineages [37]. 
Figure 
1
The product of SPLUNC1 (also called LUNX, SPURT) gene was predicted to have 256 
amino acids and to be rich in leucine [40].  The expression pattern of SPLUNC1 seems to be 
common to all mammalian species examined so far.  SPLUNC1 is expressed in the upper 
airways, the salivary gland, the oropharynx, the trachea.  It is also a major secreted protein in the 
upper respiratory tract [38] and was also detected in human saliva [39].  Some studies have shown 
that SPLUNC1 is present in submucosal glands and in some cells of the tracheal epithelium [40].  
The sites of SPLUNC1 expression correspond to locations were significant pathogenic loads are 
encountered and were bacterial sensing and/or neutralizing proteins might be required.  Those 
sites are constantly exposed to bacteria, either by virtue of new exposures or by the resident 
microbial communities, however infections are rare.  Thus epithelial expressed PLUNC might 
play a role in controlling microbial attacks within physiological limits by neutralizing pathogens, 
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diminishing their ability to grow or silencing released signaling molecules.  Ghafouri et al. 
showed that PLUNC binds LPS in vitro [41].  Based on that SPLUNC1 could be good candidate 
member of the innate immune system. 
Ghafouri et al. showed that PLUNC can be a marker of chemically induced airway 
irritation.  During the study two forms of PLUNC protein in nasal lavage fluid with molecular 
mass of 24.8kDa and 25.1kDa were found.  The proportion of two forms in healthy adults was 
about 70/30, however in smokers the proportion was altered to 50/50 [42].  In another study 
Ghafouri et al showed decreased PLUNC1 levels in nasal lavage fluid from epoxy workers with 
upper respiratory symptoms after long term exposure to organic acid anhydrides when compared 
to healthy controls.  SPLUNC1 levels in exposed individuals were 2-6 times lover than in 
controls [43].  Human SPLUNC1 was proposed as a marker of micromethastasis in non-small cell 
lung carcinoma (NSCLC).  It is found in all the lung carcinoma cell lines, and it is differentially 
expressed in lymph nodes of cancer patients [44].  SPLUNC1 has been shown to be a sensitive 
marker for the detection of NSCLC in peripheral blood samples [45].  SPLUNC1 was also 
expressed in head and squamous cell carcinoma [46] and in nasopharyngeal cancer [47].  Bingle at 
al showed that SPLUNC1 is commonly expressed in adenocarcinomas, muco-epidermoid 
carcinoma, bronchio-alveloar carcinoma [48].  Up-regulated SPLUNC1 levels were also noted 
after invasive surgery [32] and in chronic obstructive pulmonary disease (COPD) [38].  Di et al 
examined sputum of normal subjects and of patients with COPD.  The results showed that 
PLUNC1 amounts were higher in samples obtained from COPD patients when compared with 
normal subjects [38].   
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3. MATERIALS AND METHODS 
 
 
 
 
3.1. TRANSGENIC MICE GENERATION 
 
 
The expression of CCSP-spurt transgenic mice were under the transcriptional control of the 
mouse CCSP promoter.  Human spurt cDNA (0.77 kb), coding for the active, mature SPURT 
protein, was generated by RT-PCR from total RNA isolated from airway epithelial cells.  Protein 
translational start codon and 12 nucleotides of the 5' untranslated region flanking it were 
incorporated into the forward PCR cloning primer.  The primer sequences (5' to 3') used were: 
forward primer, ATA AGA ATG CGG CCG CCT AAG AGC AAA GAT GTT TC, and reverse 
primer, ATA AGA ATG CGG CCG CAC CTT GAT GAC AAA CTG.  The PCR product was 
gel purified and cloned using the pCR2.1-TOPO cloning system (Invitrogen, Carlsbad, CA) and 
sequenced. The insert was subcloned into the Not I site of the 1st exon of a mouse Clara cell 
secretory protein (mCCSP) 9.6 kb genomic sequence in a pUC19 construct vector.  The construct 
was verified by restriction enzyme digestion and sequencing.  The CCSP-spurt DNA fragment 
was then isolated from the plasmid by digestion with Sph I, and used for generation of transgenic 
mice by microinjection into mouse oocytes.  Transgenic founder mice were identified by 
Southern analysis, and the results also confirmed by PCR genotyping as described below.  
Genotyping was done by PCR using primers specific for transgene constructs as follows. CCSP 
transgene primers: forward primer in mCCSP promoter: 5’-GTT GGC AAG TCT ACA GTT 
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GC-3’, reverse primer in CCSP 1st intron region: 5’-GAA AGA GAC CCT GGG CAC TCA-3’, 
and forward primer of spurt coding region: 5’-GAC GTC AGT GAT TCC TGG CC-3’.  
 
 
 
 
3.2. RNA ISOLATION AND RT-PCR ANALYSIS 
 
 
Total RNA was isolated from lungs and trachea of wild type and transgenic mice.  RT-PCR 
analyses of Spurt were performed with the following primers: Oligo-2 (5’- GAC GGT ACC 
GAG ACC TTG ATG ACA AAC TG -3’ and Oligo-3 (5’- TAG AAT TCA GTT TGG AGG 
CCT GCC -3’.  The following program was used: denaturation at 94oC for 2min, 35 cycles 94oC 
for 30 sec, 55oC for 30sec, 68oC for 1min.  The PCR program was concluded by an extension at 
68oC for 7min.  8microliters of the amplification product was applied to 1% agarose gel and 
visualized after electrophoresis by ethidium bromide staining.  
 
 
 
3.3. REAL TIME RT-PCR ANALYSIS 
 
 
Total RNA was isolated from lungs of wild type and transgenic mice.  Real time RT-PCR 
analyses of Spurt were performed with the following primers and probes: forward 5’-
TTCAGGGCAACGTGTGCC-3’, reverse 5’-TAGTCCGTGGATCAGCATGTTAACA-3’, 
probe 5’- CTGGTCAATGAGGTTCTCAGAGGCTTGG-3’ were used to determine human 
Spurt.  Another set of primers and specific probe were used to determine mouse mPlunc: forward 
5'- TGG GAT TCT CAG CGG TTT GGA TGT -3', reverse 5'- TCA GCC AAG ATA GCC TTC 
CTT CCT -3', probe 5'- /56-FAM/CAC CCT GGT GCA CAA CAT TGC TGA AT/36-
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TAMTph/ -3'.  The following program was used: 95oC for 12min, 40 cycles 95oC for 15 sec, 
60oC for 1min.   
 
 
 
 
3.4. DEVELOPMENT OF THREE ANTIBODY SANDWICH ELISA 
 
 
Polystyrene 96 well microtiter plates (Costar, Corning Inc.) were coated with 100 µl of 3 µg/ml 
antibodies against spurt in 50mM carbonate buffer.  Four different antibodies were used: rabbit 
anti Plunc antibody (University of Miami School of Medicine, Miami, Florida), Ab1, Ab2, Ab3.  
Ab1 (S84-I99), Ab2 (A165-C180), Ab3 (Leu73-Gly86) were created by injecting rabbits with peptides 
that targets specific regions of spurt protein.  Plates were kept at 37oC in humid chamber 
overnight.  Prior to use, plates were washed and wells were blocked by addition of 200µL of 
blocking buffer (PBS – 1% BSA) and kept at 37oC for one hour.  Calibration curve was prepared 
using recombinant human PLUNC (rhPLUNC, R&D Systems, Minneapolis, MN).  Five 
different concentrations of recombinant protein were prepared (5ng/well; 10ng/well, 25ng/well, 
50ng/well, 100ng/well) and 100µl of solution was loaded into the well.  Calibration curves were 
run in duplicates.  Plates were incubated at 37oC for 1hr.  Afterwards a goat anti-human Plunc 
(R&D Systems, Minneapolis, MN) diluted 1:400 in blocking buffer was added and plates were 
incubated for 1hr at 37oC in humid chamber.  After one hour, a mouse anti goat antibody (Pierce 
Biotechnology, Inc.) was added (1:10000).  Plates were incubated at 37oC for 1hr.  In order to 
develop the plate 100µl of 1-Step Turbo TMB-ELISA (Pierce Biotechnology, Inc.) was added to 
each well.  Plate was incubated at room temperature for 30 min.  In order to stop the reaction 
100µl of 1N HCl was added to each well.  The absorbance was measured at 450nm.  Obtained 
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curves were evaluated and one with the best sensitivity and longest linear range was selected to 
use in future experiments. 
 Specificity was tested by coating multiwell plates with unrelated antibodies.  Specifically 
plates were coated with 100 µl of 3 µg/ml antibodies against PBEF-a, TTF-1, Intergrin α6 and 
with normal rabbit serum in 50mM carbonate buffer.  Plates were kept at 37oC in humid chamber 
overnight.  Prior to use, plates were washed and wells were blocked by addition of 200µL of 
blocking buffer (PBS – 1% BSA) and kept at 37oC for one hour.  Five different concentrations of 
recombinant protein (rhPLUNC, R&D Systems, Minneapolis, MN) were prepared (5ng/well; 
10ng/well, 25ng/well, 50ng/well, 100ng/well) and 100µl of solution was loaded into the well.  
Samples were loaded in duplicates and experiment was continued as described above.  Obtained 
results showed no nonspecific binding. 
 
 
 
 
3.5. THREE ANTIBODY SANDWICH ELISA 
 
 
Polystyrene microtiter plates (Costar, Corning Inc.) were coated with 6µg/mL (0.6 µg/well) 
rabbit anti-spurt antibody (Ab2) in 50mM carbonate buffer.  Plates were kept at 37oC in humid 
chamber overnight.  Prior to use, plates were washed and wells were blocked by addition of 
200µL of blocking buffer (PBS – 1% BSA) and kept at 37oC for one hour.  Calibration curve 
was prepared using recombinant human PLUNC (rhPLUNC, R&D Systems, Minneapolis, MN) 
as was described above.  30µl of sample BAL was added to the wells and diluted up to 100µl 
with blocking buffer.  Samples were added in duplicates.  Plates were incubated at 37oC for 1hr.  
Afterwards a goat anti-human Plunc (R&D Systems, Minneapolis, MN) diluted 1:400 in 
blocking buffer was added and plates were incubated for 1hr at 37oC in humid chamber.  After 
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one hour, a mouse anti goat antibody (Pierce Biotechnology, Inc.) was added (1:10000).  Plates 
were incubated at 37oC for 1hr.  In order to develop the plate 100µl of 1-Step Turbo TMB-
ELISA (Pierce Biotechnology, Inc.) was added to each well.  Plate was incubated at room 
temperature for 30 min.  In order to stop the reaction 100µl of 1N HCl was added to each well.  
The absorbance was measured at 450nm. 
 
 
 
 
3.6. SDS-PAGE 
 
 
BAL, lung homogenate and rhPLUNC (R&D Systems, Minneapolis, MN) were dilluted with 
sample loading buffer.  rhPLUNC was used as a control.  Samples were heated for 5 min at 95 
oC, and then applied to the wells of a gradient gel (NuPAGE 12% Bis-Tris Gel, Invitrogen).  
20µg of protein was added to each lane when BAL or lung homogenate was loaded into the gel.  
40µg/lane of protein was loaded for the control.  Electrophoresis was performed at 100 volts for 
10min and continued at 200 volts for 30 min.   
 
 
 
 
3.7. WESTERN BLOT ANALYSIS 
 
 
For Western blots the proteins were electroblotted onto nitrocellulose membrane (Pierce 
Biotechnology, Inc.) in transfer buffer containing 25mM Tris base, 0.2M glycine, 20% methanol 
(pH~8.5).  Membranes were blocked with 5% non fat dry milk in Tris-buffered saline with 0.1% 
Tween-20 (TBST) for 1 h.  Membranes were washed with TBST 3x for 5min and then incubated 
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with goat anti-human PLUNC antibody (R&D Systems, Minneapolis, MN) (diluted into 
blocking solution, 1:1000) overnight in 4oC.  After washing with TTBS 3x for 5 min, the second 
antibody was added and membranes were incubated for 1 h (mouse anti goat-HRP antibody 
(Pierce Biotechnology, Inc.), diluted 1:10000).  Final 3x 5min washes with TBST were 
performed.  Membrane was developed using SuperSignal West Pico Chemiluminescent 
Substrate (Pierce Biotechnology, Inc.). 
 
 
 
 
3.8. BAL TESTING FOR ANTIBACTERIAL ACTIVITY 
 
 
Pseudomonas aeruginosa was grown in LB solution for overnight.  Before using it to make serial 
dilutions, OD of bacterial stock solution was measured and adjusted to ~0.74.  After that adjusted 
bacterial stock was used for serial dilutions.  Five 1:10 dilutions were performed using 500µl of 
bacterial stock solution (OD470 ~0.740; approximately 2*10-11 bacteria) in 4500µl PBS (10-1 to 
10-5).  Dilutions were performed right before the use.  30ul of PBS, transgenic and control mice 
BAL was loaded into the wells of multiwell plate.  Samples were loaded in duplicates.  Plates 
were kept on ice while serial dilutions of bacteria were performed.  Subsequently 30µl of 10-5 
bacterial solution was added to the wells.  Samples were mixed and incubated for two hours with 
shaking.  After incubation plates were placed on ice to slow down further bacterial growth.  50µl 
of bacteria and BAL mix was plated on LB agar plate.  After plating agar plates were inverted 
and placed into 37oC incubator.  Colonies were enumerated after 24h. 
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3.9. NEUTRALIZATION OF ANTIBACTERIAL ACTIVITY BY ANTI-SPURT 
ANTIBODY 
 
 
Pseudomonas aeruginosa was grown in LB solution overnight.  Before use OD of bacterial stock 
solution was measured and adjusted to ~0.74.  After that adjusted bacterial stock was used for 
serial dilutions.  Ten 1:10 dilutions were performed using 500µl of bacterial stock solution 
(OD470 ~0.74; approximately 2*1011 bacteria) in 4500µl PBS (10-1 to 10-10).  Dilutions were 
performed right before the use.  Only three bacterial dilutions (10-8 to 10-10) were used for the 
experiment.  Mice BAL were preincubated with slight agitation for one hour at RT with normal 
rabbit serum (NRS) or with anti Plunc antibody (University of Miami School of Medicine, 
Miami, Florida).  3µl of NRS or anti Plunc antibody per 20µl of BAL was used.  After 
incubation 20ul BAL plus NRS or anti Plunc antibody was loaded into the wells of multiwell 
pate.  Plate was kept on ice while serial dilutions of bacteria were performed.  Subsequently 20µl 
of appropriate bacterial solution was added to the wells.  Samples were incubated for two hours 
with shaking.  After incubation plate was placed on ice to slow down further bacterial growth.  
LB agar plate was divided into 3 sections and 10µl of each dilution were plated 3 times.  After 
liquid soaked into the agar plates were inverted and placed into 37oC incubator. Colonies were 
enumerated after 24h.   
 
 
 
 
3.10. BACTERIAL CULTURE 
 
 
P. aeruginosa was a generous gift from Chad Steele (Department of Pediatrics, Division of 
Pulmonology Children's Hospital of Pittsburgh, University of Pittsburgh School of Medicine, 
Pittsburgh, Pennsylvania).  For each experiment, P.aeruginosa was inoculated from fresh culture 
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plate, and then incubated overnight at 37°C in a shaking incubator.  Then bacterial culture was 
centrifuged and pellet resuspended in 10ml of phosphate-buffered saline (PBS) to approximately 
1*1010 CFU*ml-1.   
 
 
 
 
3.11. MICE EXPOSURE TO PSEUDOMONAS AERUGINOSA 
 
 
Wild type and transgenic mice were exposed to aerosolized p. aeruginosa for 45min using the 
Inhalation Exposure System (Glas-Col, model A42X).  Mice were placed in a compartmentalized 
mesh basket (five chambers, each with a capacity for 20 mice). Parameters for the standard 
aerosol exposure cycle were 45min for nebulization, 15min for cloud decay, 15min for 
decontamination (UV irradiation).  For determination of initial bacterial deposition in the lungs, 
animals were sacrificed immediately after the standard exposure cycle. 
 
 
 
 
3.12. BRONCHOALVEOLAR LAVAGE (BAL) 
 
 
At each time point, 4 and 24 hours after aerosol exposure, 5 to 6 transgenic mice and non-
transgenic control mice were anesthetized with 2.5% Avertin (2% 2,2,2-tribromoethanol 2% tert-
amyl alcohol, 0.9% NaCl).  The diaphramatic lobe was tied off and the rest of the lung was 
lavaged 2 times through a tracheal cannula with total of 1 ml of sterile PBS.  BAL was collected 
and kept on ice.  Furthermore, lung was lavaged with five more separate 1ml volumes of sterile 
PBS.  The aliquots from individual mice were combined, centrifuged at 300 x g.  After 
centrifugation the supernatants were removed and cell pellets were resuspended in PBS.  The 
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cells were counted in a hemacytometer in order to obtain cell counts.  Differentials were 
performed on slides prepared in a Shandon Cytospin (ThermoShandon, Pittsburgh, PA) and 
stained with a modified Wright-Giemsa technique (Diff-Quik, Dade Behring, Dudingen, 
Switzerland). 
 
 
 
 
3.13. BACTERIAL ENUMERATION 
 
 
After excision diaphramatic lobe of the lung was placed into eppendorf tube containing 0.4ml of 
sterile PBS and kept on ice.  Later on lung was homogenized and additional 0.6ml of sterile PBS 
was added to homogenized mixture.  Six 1:10 dilutions were performed using 50µl of lung 
homogenate in 450ul PBS (10-1 to 10-6).  LB agar plate was divided into 6 sections and 10µl of 
each dilution were plated 3 times.  Plates were left on the counter top till the liquid soaked into 
the plate.  Then plates were inverted and placed into 37oC incubator. Colonies were enumerated 
after 24h. 
 
 
 
 
3.14. HISTOLOGY 
 
 
Lungs were inflated in situ with 4% paraformaldehyde, then removed and stored at 4°C in the 
same fixative.  The tissue was embedded in paraffin, sectioned, and stained with hematoxylin 
and eosin. 
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3.15. IMMUNOHISTOCHEMISTRY 
 
 
Immunohistochemical procedures were performed on treated paraffin sections.  Rehydrated 
slides were quenched in 3% H2O2 for 10 min.  Antigen retrieval was performed by boiling slides 
for 20 minutes in 10 mM citrate buffer (pH 6.0) following which sections were washed, blocked 
(0.03% casein in 0.05% PBS/Tween-20) for an hour and incubated with anti 1:200 anti human 
PLUNC (R&D Systems, Minneapolis, MN) antibody overnight at 4°C.  A mouse anti goat 
antibody (Pierce Biotechnology, Inc.) was used as a second antibody.  A serum to from 
preimmune rabbit was used as a control.  Slides were stained with Metal Enhanced DAB solution 
(Pierce Biotechnology, Inc.) and counterstained with Mayer’s hematoxylin solution (Sigma-
Aldrich Co.). 
 
 
 
 
3.16. BIO-PLEX CYTOKINE ASSAY 
 
 
Commercially available mouse Cytokine 18-Plex Panel assay (Bio-Rad Inc., cat#171F11181) 
was used to analyze BAL.  In short, anti- cytokine beads were added to the wells.  Standard 
curve was prepared following kit instructions.  50µl of each standard and 50µl of sample was 
added to appropriate wells.  Plate was incubated with shaking at room temperature.  Plate was 
washed 3x with Bio-Plex wash buffer and 25µl of detection antibody was added afterwards.  
After incubation plates was washed again and Streptavidin-Pe solution was added to each well.  
Plate was incubated for 10min with shaking.  After incubation streptavidin–Pe solution was 
removed and wells were washed 3x again with wash buffer.  Lastly, beads were resuspended in 
Bio-Plex assay buffer A, plate was shaken for 30sec and afterwards read by machine. 
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4. RESULTS 
 
 
 
 
4.1. ESTABLISHMENT OF TRANSGENIC MOUSE THAT OVER-EXPRESS 
HUMAN SPURT PROTEIN 
 
 
Our laboratory has previously identified an airway specific gene, spurt, from cDNA microarray 
analysis of primary human airway epithelium exposed to retinoic acid.  Gene expression of spurt 
is higher in sputum and tissue samples obtained from patients with chronic obstructive lung 
disease (COPD) [38].  We propose that SPURT may be involved in host defense because it is 
highly homologous to bactericidal/ permeability-increasing protein (BPI) which mediates LPS 
related bacteria killing.  
To test the antimicrobial activity of SPURT in vivo, we generated a constitutively 
overexpressing CCSP-spurt transgenic mouse line in FVB/n strain ( A).  The CCSP-spurt 
mice were generated by targeting expression of the human spurt cDNA (coding region) to the 
mouse respiratory epithelium under the direction of the 9.6-kb mouse CCSP promoter.  We used 
both RT-PCR and real time RT-PCR analyses to confirm elevated mRNA expression of CCSP-
spurt when compared with their transgenic negative littermates.  The tissue distribution of over-
expressed Hs. spurt in CCSP-spurt mice was confirmed to be only at trachea and lung and exist 
in no other tissues examined ( B).  Results of real time RT-PCR of tissues from a 
transgenic mouse from mouse founder line 60583 using primer and probe set specifically 
designed for human spurt are shown in C.  DDCt was calculated and normalized to 
Figure 2
Figure 2
Figure 2
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mouse 18S.  The mouse homologue of spurt is named plunc (palate, lung, and nasal epithelium 
clone) and express exclusively in the mouse upper airways that similar to what was observed in 
human airways.  To distinguish the expression levels of transgenic human spurt from the 
endogenous mouse plunc, all primers and probes used in our experiments are specifically 
designed and unique to only amplify gene product of either human spurt or mouse plunc.   
 
 
 
 
Figure 2  Generation and Assessment of CCSP-spurt  Transgenic Mice  
 
 
 
 
The over-expression of spurt in mouse airways was further confirmed by 
immunohistochemical staining using an anti-spurt antibody.  The significant increase of SPURT 
staining in CCSP-spurt transgenic mice as compared to wild type littermate was observed in 
airway surface epithelium ( ).  The expression of mouse plunc normally does not extend 
from upper airway region to lower airway area but in our case we observed increased staining 
Figure 3
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intensity from significantly higher expression of SPURT in the distal airway epithelium of 
transgenic mice when comparing with their wild type littermates.  The result indicated successful 
expression of transgenic spurt under CCSP promoter that drives the over-expression of spurt to 
where CCSP normally expresses ( ).   Figure 3
Figure 3  Over-expressed SPURT is observed in CCSP-spurt mice airway epithelium 
 
 
 
 
 
 
4.2. ENHANCED ANTIBACTERIAL ACTIVITY USING BAL FROM CCSP-SPURT 
MICE 
 
 
SPURT is a secretory protein and our previous data demonstrated that the gene product of spurt 
(SPURT) is secreted onto the apical side of primary human airway epithelial cultures and is 
present in clinical sputum samples.  To evaluate whether over-expressed gene product of spurt in 
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CCSP-spurt transgenic mice can be detected as a secretory protein in mouse airways, we 
examined the expression level of SPURT in bronchoalveolar lavage (BAL) fluids and lung 
homogenate from transgene negative (Tg–) and transgene positive (Tg+) littermates from line 
60583.  Samples were probed with a polyclonal antibody to the spurt.  Mouse CCSP in BALF 
and GAPDH in lung homogenate were used as internal control for normalization of mice.  The 
BAL fluids (BALF) obtained from CCSP-spurt transgenic mice showed much greater SPURT 
expression than their wildtype (Wt) littermates when examined by Western blot analyses.  Since 
our anti-spurt antibody recognizes active form of both human spurt and mouse plunc, secreted 
proteins of both over-expressed human SPURT protein and endogenous mouse PLUNC protein 
were detected in our Western analyses ( A).   Figure 4
Figure 4
Figure 4
Two antibody sandwich ELISA was also used to compare SPURT levels in BAL from 
transgenic and wild type littermates.  B shows the dramatic increase of secreted SPURT 
in BAL from transgenic mice.  Results showed about ~5 fold increase in concentration of the 
potential functional SPURT protein. 
We then examined whether the BALF from unchallenged CCSP-spurt transgenic mice 
that overexpress SPURT exhibited antibacterial bio-activity.  We established a biological assay 
in vitro to assess colony formation unit (CFU) using BALF.  After optimization of experimental 
assay conditions, we mixed equal volumes of BALF with serial diluted P. aeruginosa (PAO1) 
and incubated mixtures for 2 hours at 225rpm before plating onto LB agar in triplicate.  Plates 
were incubated at 37oC for 24 hours before counting for CFU.  Numbers of CFU counts using 
BALF from CCSP-spurt mice were consistently 50% to 60% lower than BALF from wild-type 
mice (n=7) ( C).   
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Figure 4  Enhanced antibacterial activity using BALF from CCSP-spurt transgenic mice. 
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To further confirm the decreased CFUs in CCSP-spurt BALF were specifically due to 
increased SPURT overexpression, we used anti-plunc (spurt) antibody to neutralize the 
functional SPURT (spurt protein) in BALF.  Normal rabbit sera (NRS) or anti-plunc rabbit 
antisera were pre-incubated with BALF (1:10 ratio) from both Wt (n=8) and CCSP-spurt mice 
(n=8) at 25oC for 1 hour before BALF from mice were incubated with P. aeruginosa at 37oC and 
followed up with plating in triplicate.  BALF obtained from CCSP-spurt had only 51% of CFU 
counts compared to BALF from wild-type mice.   
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Figure 5  Neutralization of antibacterial activity by anti-plunc (spurt) antibody. 
 
 
 
Adding anti-plunc antisera into BALF of CCSP-spurt mice increased the average CFU 
counts significantly to more than twice the average CFU counts from Wt BALF with NRS and 
about 4x CFU counts from CCSP-spurt with NRS.  Interestingly, adding anti-plunc antisera into 
BALF of Wt mice also increased the average CFU counts when compared with Wt+NRS (Figure 
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5).  The increased CFU counts after adding anti-plunc antibody may represent the antibacterial 
activity contributed by endogenous mouse plunc.  There was no statistically significance when 
we compared the average CFU counts from both groups of Wt and Tg mice after preincubation of 
BALF with plunc antisera (Figure 5). 
 
 
 
 
4.3. INCREASED ANTIBACTERIAL ACTIVITY OF CCSP-SPURT MICE AFTER 
AEROSOLIZED PSEUDOMONAS AERUGINOSA EXPOSURE 
 
 
To examine the feasibility and to establish a mouse model for our proposed studies in this 
application regarding bacterial infection, both wild-type littermates and CCSP-spurt mice were 
aerosolized with or without P. aeruginosa (PAO1) bacteria.  Administration of bacteria into the 
respiratory tract of mice was accomplished by aerosolization of bacteria in a whole-animal 
chamber for 45 min, as previously described [49].  Four hours and twenty-four hours after 
infection, right lungs were homogenized in 1ml of sterile PBS, serially diluted, and quantitatively 
cultured on LB agar.  Colonies were counted after 24h incubation at 37°C.  1010/ml of bacteria 
(P. aeruginosa, PAO1) aerosolized for 45 min is an applicable concentration to induce acute 
mouse airway infection.  These conditions resulted in an average of ~2 x 106 CFU/lung (~ 5 x 
105/ diaphramatic lobe of lung) at the time point immediately after exposure.  (n=5~6 for each 
experimental group)   
We observed differences in the outcome between transgenic CCSP-spurt group and Wt 
group of mice after inhalation of P. aeruginosa.  Transgenic CCSP-spurt mice displayed more 
active and less lethargic behavior than their wild-type littermates at four hours following 
aerosolized inoculum of P. aeruginosa.  Both CCSP-spurt and wild type control groups of mice 
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effected more than 4-fold reduction in the number of bacteria in their lungs with signs of illness 
largely resolved by 24 hours and no sign of in respiratory distress was observed.  No mice 
(control or CCSP-spurt) died after inoculum in our repeated experiments (n=5).  P. aeruginosa 
replicated more in the lungs of Wt mice and that resulted in greater numbers of bacteria recovered 
from their lungs ( ).     Figure 6
Figure 6  CCSP-spurt mice are more resistant to lung infection with P. aeruginosa. 
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4.4. DECREASED NEUTROPHILS INFILTRATION IN LUNGS OF CCSP-SPURT 
MICE AFTER AEROSOLIZED PSEUDOMONAS AERUGINOSA EXPOSURE 
 
 
After bacterial exposure, we observed rapid production of proinflammatory cytokines and 
recruitment of neutrophils in response to P. aeruginosa challenge.  Although the average cell 
differential counts of inflammatory cells in BAL were not statistically different between wild 
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type and CCSP-spurt transgenic mice, control group of wild type mice were consistently having 
a greater number of neutrophils in their BAL than in Tg positive mice in both 4h and 24h after 
bacterial exposure ( ). Figure 7
Figure 7 Total cell numbers of neutrophils were less in CCSP-spurt mice BAL than wild-type 
littermates.   
 
 
 
 
 
 
 
Before, the bacterial exposure, the BAL cell populations of uninfected CCSP-spurt and 
control wild type mice did not differ in either total cell number (2 x 105/lung) or differential 
composition (>99% macrophages, data not shown).  By 4h after aerosolized p. aeruginosa 
exposure, neutrophils accounted for more than 90% of BAL cells in both groups of mice.  Since 
the total inflammatory cells in BAL were higher in wild type group of control mice, the total cell 
numbers of neutrophils would subsequently be lower in CCSP-spurt transgenic mice than wild 
type mice.  Total protein concentrations in BALF were not of statistical significance at time 
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points of 4h and 24h after bacteria instillation and suggested that the exposure did not 
significantly change lung permeability (data not shown).  Additionally, we did not notice any 
significant difference in regards to Lactate dehydrogenase (LDH) activity in BALF at all time 
points examined (data not shown).  These results suggest that there was no detectable acute lung 
injury after infection during the experimental time intervals. 
Wild-type and CCSP-spurt mice without P. aeruginosa exposure were used as a control 
and sacrificed to harvest lung tissues.  The lung tissues of uninfected wild-type and CCSP-spurt 
mice were both histologically normal ( ). Figure 8
Figure 8  Histological view of wild type and CCSP-spurt transgenic mice before P. aeruginosa 
exposure.   
 
 
 
 
 
 
 
However, the histological patterns of lung inflammation and injury after inhalation of P. 
aeruginosa differed noticeably between CCSP-spurt and wild type control mice.  At 4h after 
aerosolized Pseudomonas aeruginosa exposure, the lungs of control mice revealed 
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predominantly perivascular but also peribronchial and alveolar neutrophilic infiltrates associated 
with prominent edema and hemorrhage while Tg-spurt mice expressed much less severe 
neutrophilic infiltrates and alveolar hemorrhage (Figure 9).   
 
 
Figure 9  Decreased n ld type 
4.5. DECREASED PRO-INFLAMATORY CYTOKINE PRODUCTION IN CCSP-
SPURT MICE AFTER AEROSOLIZED PS  
To evaluate whether pro-inflammatory cytokine production changed after Pseudomonas 
aerugin
 
 
eutrophils infiltration and lung injury in CCSP-spurt mice than wi
mice 4h after P. aeruginosa exposure.   
 
 
 
 
EUDOMONAS AERUGINOSA EXPOSURE
 
 
osa exposure, BALF were collected from mice of each group after bacterial challenge.  
Levels of multiple cytokines (pg/ml) were measured in BAL specimens by Bio-plex assay.  
Cytokine productions were measured in unchallenged specimens as well as at 1h, 4h and 24h 
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after bacterial exposure.  First columns ( ) in each exposure group (yellow bars) 
represent wild type control mice, second correspond to transgenic mice (green bars).   
Figure 10
Figure 10  Decreased pro-inflammatory cytokine production in CCSP-spurt mice. 
 
 
 
 
 
 
 29
Of the multiple cytokines examined, tumor necrosis factor alpha (TNFα) increased 
rapidly (within 1 hour) after PAO1 bacteria instillation.  Interestingly, pro-inflammatory 
cytokines such as IL-1β, IL-6, IL-17 and GM-CSF were all lower in CCSP-spurt mice than Wt 
mice at 4h and 24h after bacterial challenge ( ).  We did not observe significant 
difference between CCSP-spurt and wild type mice in regards to the production of RANTES.   
Figure 10
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5. DISCUSSION 
 
 
 
 
Effective host defense against microbial invasion requires an innate immune system whose 
response is both rapid and independent of prior exposure [50].  There are a variety of proteins that 
participate in innate immune response.  SPURT, also named SPLUNC1, seems to be one of 
them.  It is a secreted protein that is expressed in the secretory ducts and submucosal glands of 
tracheobronchial tissues [24].  It is structurally related to bactericidal/permeability-increasing 
protein (BPI) and lipopolysaccaride binding protein (LBP), which have been demonstrated to be 
important to the host defense against gram-negative bacteria.  SPURT/SPLUNC1 belongs to the 
short-peptide subfamily of PLUNC family proteins and has homology only to the N-terminal 
domains of BPI that has previously been shown to have direct bactericidal activity.  Therefore, 
SPURT/SPLUNC1 may play a similar role to BPI in the innate immune response against 
bacteria.  However, this will represent a unique mechanism of antimicrobial activity originated 
from airway epithelium since SPURT/SPLUNC1 only expresses in airway epithelial cells. 
In this work, a newly established transgenic mouse model that over-expresses human 
spurt gene has been described.  Our results showed that spurt was specifically expressed only in 
the trachea and lung of CCSP-spurt transgenic mice as its tissue expression was driven by a 
mouse CCSP promoter.  We have also confirmed the much higher mRNA expression level of 
spurt message in CCSP-spurt transgenic mice than their wild type littermates by a real time RT-
PCR assay that specifically amplified human spurt but not the endogenous mouse plunc gene.  
Mature and secretory SPURT protein was also detected in mice BALF by both Western blot 
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analyses and ELISA.  Protein levels of SPURT were much higher in transgenic mice BALF 
when compared to their wild type littermates.  We subsequently used these newly established 
CCSP-spurt transgenic mice to evaluate effects of SPURT on bacterial clearance and 
inflammation. 
Despite sequence similarity and functional suggestion by bioinformatic searches, there 
was little direct evidence that SPURT/SPLUNC1 protein does have antimicrobial functions and 
play a role in host defense against pathogens.  Parotid secretory protein (PSP), another protein 
member in the PLUNC gene family, has been shown to bind to bacterial membranes [51].  
SPLUNC1 has also been suggested to bind directly to Escherichia coli lipopolysaccharide [41] 
and is present in the antimicrobial fraction of nasal secretions [52].  Using a bio-activity assay to 
test antimicrobial functions of secretory proteins in BALF against bacteria, our results showed 
that there was a significant decrease in CFU counts of P. aeruginosa in co-incubating with 
BALF from CCSP-spurt transgenic mice than with BALF from wild type littermates and these 
data strongly suggested that over-expression of SPURT in mouse airways may increase anti-
microbial activity of mice.  
To further prove that the increased anti-microbial activity by CCSP-spurt transgenic mice 
BALF actually happens in live mouse airways, we adapted a bacterial exposure model by 
aerosolizing P. aeruginosa into mouse airways.  The bacteria-containing mist was aerosolized, 
inhaled and bacteria were subsequently deposited into mouse airways.  Similar to the results 
from in vitro bio-activity assays, decreased CFU counts were consistently observed in the lung 
homogenates from transgenic mice than their wild type littermates after aerosolized p. 
aeruginosa exposure.  Additionally, there was significant difference observed in pathological 
examination of respiratory tracts between transgenic and wild type animals after aerosolized 
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exposure to P. aeruginosa.  There was much more noticeable damage to the lung tissues in wild 
type animals comparing with their transgenic counterparts.  Neutrophil infiltration into lung 
tissue was much less in CCSP-spurt transgenic mice than from wild type littermates.  
Furthermore, the total cell counts of neutrophils in BAL were also constantly lower in transgenic 
mice.  Taken together, our data suggest there is a lower degree of neutrophils recruitment and 
subsequent lung inflammation in CCSP-spurt transgenic mice than their wild type littermates.  
This observation suggests that overexpressing of spurt may provide an airway epithelial cell 
specific protection against opportunistic pathogens such as P. aeruginosa.   
Cytokines are frequently involved in normal regulation of all physiological processes.  
The role that cytokines play in the regulation and modulation of immunological and 
inflammatory processes is striking.  Lung is particularly dependent on tightly regulated 
immunological and inflammatory processes since it is exposed to a large variety of infectious 
agents as well as a diverse group of noxious gases and particulates during the process of gas 
exchange.  Lung defends itself from these injurious agents by deploying cytokine-regulated host 
defense mechanisms.  The use of a transgenic mouse model for in vivo studies provided an 
opportunity to identify potential changes in cytokines poroduction before and after aerosolized 
infection of P. aeruginosa.  Pro-inflammatory cytokines such as IL-1β, IL-6, IL-17 and TNF-α 
were almost non detectable prior to the bacterial exposure but significantly increased after the 
challenge.  Usually following the recognition of microbial products, TLR-mediated signaling 
results in the production of TNF-α and IL-1ß[53, 54, 55].  Neutrophil recruitment is dependent on the 
orchestrated generation of these two early-response cytokines.  These substances usually play 
beneficial roles in the body's defense systems.  However, in some instances, they may be 
released in overly-abundant amounts and cause too much inflammation in the lung.  The 
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exacerbated inflammatory response could even contribute to inflammation and dysfunction in 
other organs, such as the kidneys and liver, if these inflammatory mediators are overly released 
into the bloodstream.  Therefore, a well-regulated release of pro-inflammatory mediators is 
critical to an effective host defense.  In our studies, the enhanced lung clearance of inhaled 
bacteria also correlated with decreased measurement of pro-inflammatory cytokines (including 
IL-1β, IL-6, IL-17 and GM-CSF) in BALF from CCSP-spurt mice than wild type mice at both 
4h and 24h time points after bacterial challenge.  Another pro-inflammatory chemokine, KC, has 
been shown to substantially attenuate the accumulation of neutrophils in the lungs after the 
intratracheal administration of LPS [56].  We also observed significant lower levels of KC 
secretion in BALF from CCSP-spurt mice when compared to wild type littermates after P. 
aeruginosa exposure.  The lower amount of KC in BALF of CCSP-spurt mice might account for 
less neutrophil infiltration and resulted in lesser damage to the lung in transgenic mice as 
compared to their wild type littermates. 
Several potential mechanisms may help to explain the enhanced protection against 
bacteria that was observed in CCSP-spurt transgenic mice than wild type mice.  The first maybe 
a direct bacterial killing function of SPURT that could effectively decrease available amount of 
bacteria and only the surviving bacteria can form the colonies in mice lungs.  The second 
possible way is through a bacterial-static mechanism so that SPURT binds to bacteria and 
prevent efficient propagation of bacteria so host lung will have a longer reaction time to clear 
inhaled bacteria.  There is also a possibility that the better bacterial clearance observed in CCSP-
SPURT transgenic mice was due to increased interaction of spurt to other antimicrobial proteins 
and peptides such as defensin and subsequently potentiate antibacterial activity in transgenic 
mice.   
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6. CONCLUSIONS 
 
 
 
 
In conclusion, we confirmed in this study the antibacterial activity of spurt using both in vitro 
and in vivo approaches.  We also demonstrated that CCSP-spurt transgenic mice exhibited 
significantly better resistance to P. aeruginosa infection.  However, more studies need to be done 
in order to fully understand the function of SPURT and mechanisms of how bacteria were 
effectively decreased in CCSP-spurt transgenic mice.  Given the emergence of highly resistant 
bacterial pathogens and the increasing population of immunocompromised hosts, the treatment of 
bacterial infection has and will continue to be quite difficult.  A better understanding of airway 
epithelial cells specific and initiated host defense may provide an alternative approach to 
efficiently combat airway bacterial infection.  This alterative approach could even be tested in 
future pharmaceutical use in creating new antimicrobial drugs or treating patients with 
recombinant SPURT/SPLUNC1 proteins that naturally exist in airways. 
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